Kite Pharma enters into licensing agreement with NIH
Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health (NIH) that will give it the IP rights to T-cell therapies developed to treat cancer.
In partnership with the National Cancer Institute (NCI), a department of the NIH, Kite Pharma will develop T-cell-based receptor (TCR) products designed to treat the antigen NY-ESO-1.
Under the cooperative research and development agreement, Kite Pharma will be given the rights to develop and commercialise the TCR products from the clinical trials.
The NCI is conducting phase two of a trial that targets the NY-ESO-1 antigen, which is found in different types of cancerous tumours including sarcoma and those found in the bladder.
The agreement will see the biotech company make regular payments to the NIH, as well as pay royalties to use some of the IP protecting the T-cell therapies.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk